// App-Quantinova.ai

P051 : Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation For Multiple Sclerosis

Researchers

Presenter

  • J. A. Cohen

Principal Investigators

  • G. E. Georges

  • L. M. Griffith

  • K. Steinmiller

  • W. T. Barry

  • K. M. Harris

  • K. Ryker

  • J. Rice

  • P. Tosta

  • S. McCarthy

  • J. S. Goldstein

  • J. McNamara

  • D. Miller

  • J. J. Carlson

  • D. L. Arnold

  • D. E. Smilek

  • P. A. Muraro

Medical Centers

  • Mellen Center for MS Treatment and Research, Cleveland Clinic Lerner College of Medicine, Cleveland, OH

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD

  • Inc., Durham, NC

  • Biomarker and Discovery Research, Immune Tolerance Network, Massachusetts General Hospital, Bethesda, MD

  • Clinical Trials Group, Immune Tolerance Network, University of California San Francisco, San Francisco, CA

  • The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle

  • 2Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University Montreal QC Canada

Locations

  • United States

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • National Institute of Allergy and Infectious Diseases (NIAID)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved